Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2022-04-29 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
独立董事关于第四届董事会第二次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a pre-approval opinion from independent directors regarding agenda items for an upcoming board meeting, specifically about related party transactions and the reappointment of an audit firm. It references governance rules and internal control audit matters but does not contain financial statements or detailed financial data. The document is short (551 characters) and serves as a governance-related announcement rather than a full report. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board matters and management decisions.
2022-04-29 Chinese
独立董事关于带强调事项段无保留意见的内部控制审计报告的独立意见
Audit Report / Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding an internal control audit report with an emphasis of matter paragraph issued by an accounting firm for the fiscal year 2021. It discusses the internal control audit report specifically, not the full annual report or financial statements. The document is short (743 characters) and focuses on the audit report of internal controls, which is a standalone audit-related document. Therefore, it fits the category of Audit Report / Information (AR). FY 2021
2022-04-29 Chinese
董事会关于带强调事项段无保留意见的内部控制审计报告的专项说明
Audit Report / Information Classification · 95% confidence The document is a special statement from the board of directors of Lingkang Pharmaceutical Group Co., Ltd. regarding an internal control audit report with an emphasis paragraph issued by Tianjian Accounting Firm for the year 2021. The document discusses the audit findings related to internal control deficiencies, the board's review and agreement with the audit report, and the corrective measures taken by the company. The document is not the audit report itself but a board statement explaining and responding to the audit report's emphasis paragraph. It does not contain full financial statements or detailed audit results but focuses on internal control audit issues and board commentary. Given the nature of the document as a board explanation and response to an audit report, it fits best under Audit Report / Information (AR), which covers standalone audit reports and related information excluding full annual reports. The document length is short (1427 characters), but it contains substantive content about the audit findings and board actions, not merely an announcement or certification. Therefore, the classification is AR with high confidence. FY 2021
2022-04-29 Chinese
2021年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the company's 2021 profit distribution plan, including dividend payment details, board and independent directors' opinions, and supervisory board opinions. It discusses the proposed cash dividend per share, total dividend amount, and the need for shareholder approval at the upcoming annual general meeting. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution plan and related approvals. This fits the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders.
2022-04-29 Chinese
中信证券股份有限公司关于灵康药业集团股份有限公司可转换公司债券募集资金投资项目延期的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the delay in the investment project funded by the convertible bonds issued by Lingkang Pharmaceutical Group Co., Ltd. It discusses the fundraising amount, project investment, reasons for delay, impact, and approvals by the board and supervisory committee. It references regulatory approvals and compliance with stock exchange rules. The document is not a full financial report but a regulatory compliance and verification statement related to the use of raised funds and project delays. It does not contain financial statements or earnings data, nor is it a simple announcement of a report. This fits best under Regulatory Filings (RNS) as it is a regulatory compliance document related to fundraising and project progress, not a financial report or announcement of voting results or capital changes.
2022-04-29 Chinese
关于可转换公司债券募集资金投资项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the extension of the investment project timeline funded by proceeds from a convertible bond issuance. It details the background of the fundraising, the use of funds, the reasons for the delay, and includes opinions from independent directors, the supervisory board, and the sponsoring institution. The document does not contain financial statements or detailed financial data but is a formal disclosure about a capital project timeline change related to fundraising proceeds. It is not a full financial report, audit report, or earnings release. It is an update on a financing-related matter, specifically about the use and timing of funds raised through convertible bonds. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 3224 characters, which is consistent with an announcement rather than a full report.
2022-04-29 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.